Dermira, Inc. (DERM) News

Dermira, Inc. (DERM): $5.47

0.09 (+1.67%)

POWR Rating

Component Grades








Add DERM to Watchlist
Sign Up

Industry: Biotech




in industry

Filter DERM News Items

DERM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

DERM News Highlights

  • For DERM, its 30 day story count is now at 20.
  • Over the past 21 days, the trend for DERM's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about DERM are DRUG, LYRA and AGE.

Latest DERM News From Around the Web

Below are the latest news stories about JOURNEY MEDICAL CORP that investors may wish to consider to help them evaluate DERM as an investment opportunity.

Here's What Could Help Journey Medical Corporation (DERM) Maintain Its Recent Price Strength

Journey Medical Corporation (DERM) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Yahoo | December 27, 2023

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics

Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics are part of the Zacks top Analyst Blog.

Yahoo | December 27, 2023

What Awaits These 4 Drug Stocks That More Than Doubled in 2023?

Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.

Yahoo | December 26, 2023

argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study

argenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls.

Yahoo | December 21, 2023

Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA

The CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise.

Yahoo | December 20, 2023

4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow

Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.

Yahoo | December 20, 2023

Invivyd (IVVD) Surges on Positive Data From COVID-19 Study

Invivyd (IVVD) reports positive initial data from the phase III CANOPY study on VYD222 for the prevention of symptomatic COVID-19. Stock shoots up on the news.

Yahoo | December 19, 2023

Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis

The FDA approves Arcutis' (ARQT) NDA for Zoryve topical foam 0.3% for treating seborrheic dermatitis in individuals nine years of age and above.

Yahoo | December 19, 2023

Journey Medical Corporation (NASDAQ:DERM) Surges 69% Yet Its Low P/S Is No Reason For Excitement

Despite an already strong run, Journey Medical Corporation ( NASDAQ:DERM ) shares have been powering on, with a gain of...

Yahoo | December 18, 2023

Apellis (APLS) Falls on Europe Update for Pegcetacoplan in GA

The CHMP may adopt a negative opinion on Apellis' (APLS) intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration in the EU. Stock declines.

Yahoo | December 15, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!